Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease-Reference-Cited by-同舟云学术

Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease

Published:2020-12 Issue: Volume:207 Page:112751
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Jiang Xueyang^ORCID,Zhou Junting,Wang Yang,Chen Lei,Duan Yan^ORCID,Huang Jianping^ORCID,Liu Chang,Chen Yao,Liu Wenyuan,Sun Haopeng,Feng Feng,Qu Wei

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference57 articles.

1. The discovery of Alzheimer’s disease;Hippius;Dialogues Clin. Neurosci.,2003

2. Alzheimer’s disease facts and figures;Alzheimer’s Association;Alzheimers. Dement,2020

3. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine;Zemek;Expet Opin. Drug Saf.,2014

4. Drugs in clinical trials for Alzheimer’s disease: the major trends;Bachurin;Med. Res. Rev.,2017

5. Trial of Solanezumab for mild dementia due to Alzheimer’s disease;Honig;N. Engl. J. Med.,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies;Signal Transduction and Targeted Therapy;2024-08-23

2. Recent Molecular Targets and Their Ligands for the Treatment of Alzheimer Disease;Current Topics in Medicinal Chemistry;2024-08-20

3. GSK3: A potential target and pending issues for treatment of Alzheimer's disease;CNS Neuroscience & Therapeutics;2024-07

4. Design, Synthesis, and Biological Evaluation of Novel Tetrahydroacridin Hybrids with Sulfur-Inserted Linkers as Potential Multitarget Agents for Alzheimer’s Disease;Molecules;2024-04-14

5. Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease;Drug Discovery Today;2024-04